A clinical trial involving semaglutide was registered on October 16, 2026. The trial, titled "Dietary, Medication, and Endoscopic Interventions for Post-Bariatric Hypoglycemia," is listed under identifier NCT07878494.
According to the registry entry, the study status is not yet recruiting. The trial phase is listed as not applicable.
The study is designed to examine dietary, medication, and endoscopic interventions for post-bariatric hypoglycemia. Semaglutide is approved and is included as part of the interventions under evaluation in this registered trial.
No participants have been enrolled yet, as the trial has not opened recruitment. No results, outcomes, or safety findings have been reported at this stage, since the study has not begun.
Further details, including eligibility criteria and study design specifics, are available through the official trial registry listing. Updates to recruitment status or trial progress would be expected to follow standard clinical trial registry reporting as the study advances.
Readers interested in background on semaglutide, including its approved uses and general profile, can consult the compound overview for additional context.